Gimv et al. sell ActoGenix for $60m

The sale price comprises $30m in cash for ActoGenix's shareholders, as well as a further $30m of Intrexon common stock.

Intrexon is a New York Stock Exchange-listed business specialising in synthetic biology.

Previous funding
ActoGenix first received funding in October 2006, securing €20m from lead investor Gimv – which invested via the Biotech Fonds Vlaanderen – as well as Life Sciences Partners (LSP), Aescap Venture and Natixis Private Equity.

In February 2009, the company pulled in a further €13.5m from LSP, Aescap, Gimv, Biovest, Baekeland Fonds and Natixis.

In April 2013, ActoGenix's existing shareholders were joined by Saffelberg Investments in a €10.7m series-C round.

Company
ActoGenix was founded in 2006 as a spinout from the Flanders Institute of Biotechnology and the University of Ghent.

The Ghent-headquartered company is a developer of biological therapies designed to improve the treatment of gastrointestinal, immunological and metabolic diseases.

It has developed ActoBiotics, an oral treatment of therapeutic proteins.

People
Bernard Coulie is the CEO of ActoGenix. Patrick Van Beneden is a partner on Gimv's health & care team.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Exits
• Healthcare
• Belgium
• Gimv
• Trade sale